Small Molecules Enhance Exon Skipping for DMD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current exon skipping therapies for Duchenne muscular dystrophy (DMD) face challenges in achieving broad and sustained dystrophin expression across multiple muscle groups, often requiring high doses of antisense oligonucleotides, which are costly and have toxicity issues.
Innovation Solution
The use of small molecule compounds, such as dantrolene, that synergize with antisense oligonucleotides to enhance exon skipping, increasing dystrophin mRNA and protein expression by modulating mRNA splicing, thereby reducing the need for high doses of oligonucleotides and minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of antisense oligonucleotides are administered to achieve sustained dystrophin expression across multiple muscle groups, then therapeutic efficacy is improved, but cost and toxicity increase
Solution Approach 1:
The patent changes the chemical parameters of the oligonucleotide backbone by transitioning from phosphodiester to phosphorothioate modifications. This parameter change enhances the stability and binding affinity of the antisense oligonucleotide, allowing for reduced dosing while maintaining therapeutic efficacy. The phosphorothioate modification specifically addresses toxicity issues by improving pharmacokinetic properties and reducing off-target effects.
Solution Approach 2:
The patent employs composite oligonucleotide structures combining different chemical modifications (2'-O-methyl, phosphorothioate) within the same molecule. This composite approach creates molecules with optimized properties: the 2'-O-methyl portion enhances affinity and specificity, while the phosphorothioate portions improve stability and reduce toxicity. This composite material strategy resolves the contradiction between efficacy and toxicity by integrating multiple functional elements into a single therapeutic agent.
2Reliability
If high doses of antisense oligonucleotides are administered to achieve sustained dystrophin expression, then therapeutic efficacy is improved, but treatment cost increases
Solution Approach 1:
The patent implements parameter changes in the oligonucleotide chemical structure (phosphorothioate backbone, 2'-O-methyl modifications) that directly impact dosing requirements. These structural changes increase the potency and duration of action of each administered molecule, thereby reducing the quantity of substance needed to achieve the same therapeutic effect. This resolves the contradiction between efficacy and dosage quantity.
3Reliability
If frequent dosing is performed to maintain dystrophin expression levels, then therapeutic efficacy is improved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent applies the principle of partial action by using lower frequencies of dosing than would be required for unmodified oligonucleotides. The phosphorothioate and 2'-O-methyl modifications extend the half-life and persistence of dystrophin expression, allowing treatment intervals to be extended while maintaining therapeutic efficacy. This reduces the operational burden on patients while sustaining the necessary expression levels.
Solution Approach 2:
The chemical parameter changes in the oligonucleotide structure directly affect the pharmacokinetic profile, extending the duration of action. This parameter modification allows for less frequent administration while maintaining sustained dystrophin expression, thereby resolving the contradiction between expression sustainability and dosing frequency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Dantrolene and other identified compounds significantly enhance exon skipping in both cell cultures and mouse models, leading to increased dystrophin protein levels and improved muscle function, potentially offering a more practical and effective treatment for DMD.
Implementation Method 1
small molecule compounds, such as dantrolene, that synergize with antisense oligonucleotides to enhance exon skipping, increasing dystrophin mRNA and protein expression by modulating mRNA splicing
Data Source
AI summary
This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a small molecule selected from the compounds shown in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.